Login to myESAIC Membership


The ESAIC is dedicated to supporting professionals in anaesthesiology and intensive care by serving as the hub for development and dissemination of valuable educational, scientific, research, and networking resources.



The ESAIC hosts the Euroanaesthesia and Focus Meeting congresses that serve as platforms for cutting-edge science and innovation in the field. These events bring together experts, foster networking, and facilitate knowledge exchange in anaesthesiology, intensive care, pain management, and perioperative medicine. Euroanaesthesia is one of the world’s largest and most influential scientific congresses for anaesthesia professionals. Held annually throughout Europe, our congress is a contemporary event geared towards education, knowledge exchange and innovation in anaesthesia, intensive care, pain and perioperative medicine, as well as a platform for immense international visibility for scientific research.


Professional Growth

The ESAIC's mission is to foster and provide exceptional training and educational opportunities. The ESAIC ensures the provision of robust and standardised examination and certification systems to support the professional development of anaesthesiologists and to ensure outstanding future doctors in the field of anaesthesiology and intensive care.



The ESAIC aims to advance patient outcomes and contribute to the progress of anaesthesiology and intensive care evidence-based practice through research. The ESAIC Clinical Trial Network (CTN), the Academic Contract Research Organisation (A-CRO), the Research Groups and Grants all contribute to the knowledge and clinical advances in the peri-operative setting.

Learn more about the ESAIC Clinical Trial Network (CTN) and the associated studies.


EU Projects

The ESAIC is actively involved as a consortium member in numerous EU funded projects. Together with healthcare leaders and practitioners, the ESAIC's involvement as an EU project partner is another way that it is improving patient outcomes and ensuring the best care for every patient.


Patient Safety

The ESAIC aims to promote the professional role of anaesthesiologists and intensive care physicians and enhance perioperative patient outcomes by focusing on quality of care and patient safety strategies. The Society is committed to implementing the Helsinki Declaration and leading patient safety projects.



To ESAIC is committed to implementing the Glasgow Declaration and drive initiatives towards greater environmental sustainability across anaesthesiology and intensive care in Europe.



The ESAIC works in collaboration with industry, national societies, and specialist societies to promote advancements in anaesthesia and intensive care. The Industry Partnership offers visibility and engagement opportunities for industry participants with ESAIC members, facilitating understanding of specific needs in anaesthesiology and in intensive care. This partnership provides resources for education and avenues for collaborative projects enhancing science, education, and patient safety. The Specialist Societies contribute to high-quality educational opportunities for European anaesthesiologists and intensivists, fostering discussion and sharing, while the National Societies, through NASC, maintain standards, promote events and courses, and facilitate connections. All partnerships collectively drive dialogue, learning, and growth in the anaesthesiology and intensive care sector.



Guidelines play a crucial role in delivering evidence-based recommendations to healthcare professionals. Within the fields of anaesthesia and intensive care, guidelines are instrumental in standardizing clinical practices and enhancing patient outcomes. For many years, the ESAIC has served as a pivotal platform for facilitating continuous advancements, improving care standards and harmonising clinical management practices across Europe.



With over 40 years of publication history, the EJA (European Journal of Anaesthesiology) has established itself as a highly respected and influential journal in its field. It covers a wide range of topics related to anaesthesiology and intensive care medicine, including perioperative medicine, pain management, critical care, resuscitation, and patient safety.



Becoming a member of ESAIC implies becoming a part of a vibrant community of nearly 8,000 professionals who exchange best practices and stay updated on the latest developments in anaesthesiology, intensive care and perioperative medicine. ESAIC membership equips you with the tools and resources necessary to enhance your daily professional routine, nurture your career growth, and play an active role in advancing anaesthesiology, intensive care and perioperative medicine.

Membership opportunities
at the ESAIC


EA20 Newsletter: Session 09L1: Hot topics in intensive care medicine - Last 12 months' top publications

Saturday 28 November, 1500-1545H, Channel 2

In this session, Professor Christian Putensen, University Hospital Bonn, Germany, will review some important papers across various areas of intensive care medicine, including COVID-19, ARDS,  sepsis, vasopressor therapy, acute kidney injury, nutrition and vitamins, and sedation and delirium. Some of his selections are outlined below – to hear about these and the many other interesting research highlights of 2020, please join him for his session this afternoon.



Prof Putensen will cover several papers relating to remdesivir, including:

JAMA: Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19 – A Randomized Clinical Trial


Patients were given a 5-day regimen of remdesivir or a 10-day regimen, versus standard care. The loading dose was 200mg intravenously followed by 5 days or 10 days of 100mg doses intravenously each day. The data showed improved outcomes in the 5-day treatment group versus standard of care, but no improvement in the 10-day treatment group.

The Lancet: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial


This study assessed 237 patients, randomised 2:1 to remdesivir or placebo. The loading dose was 200mg intravenously, followed by 100mg intravenously from days 2-10. The primary endpoint was time to clinical improvement up to day 28, and the results showed no difference between the groups in time to clinical improvement or drop in viral load.

NEJM: Remdesivir for treatment of COVID-19 – final report


This double blinded multicentre RCT assessed 1062 hospitalised COVID-19 patients, 15% with mild-to-moderate disease and 85% with severe disease.  Patients were randomised 1:1 to placebo or remdesivir 200mg intravenous loading dose, followed by 100mg intravenously on days 2-10. The primary outcome was time to recovery up to day 28. The median time to recovery was 10 days with remdesivir and 15 days with placebo, but only in patients receiving supplementary oxygen – not those on mechanical ventilation.

Other studies on COVID treatment with hydrocortisone and dexamethasone will also be covered in this presentation.



The Lancet Respiratory Medicine: Effect of aspirin on deaths associated with sepsis in healthy older people (ANTISEPSIS): a randomised, double-blind, placebo-controlled primary prevention trial


This is a multi-centre double-blinded RCT, and a sub-study of ASPREE (Aspirin in reducing events in the elderly trial). This assessed 16,703 participants 70 years or over, randomised to oral aspirin 100mg a day or placebo. Sepsis was defined by infection plus 2 out of 4 systemic inflammatory response syndrome (SIRS) criteria. The study found no effect of aspirin, and concluded daily low-dose aspirin treatment did not reduce deaths associated with sepsis in older adults.



NEJM: Timing of renal replacement therapy in acute kidney injury


This multinational multicentre RCT assessed 2900 patients. In the accelerated strategy group, RRT began within 12 hours, versus the standard group strategy that used existing protocols and parameters to determine when to begin RRT. There was no difference in mortality between the groups, but at 90 days 10% of patients in the accelerated group remained dependent on dialysis compared to 6% in the standard therapy group. Thus, early RRT appears to increase the risk of long-term dependence on dialysis.



NEJM: Early high-dose vitamin D3 for critically ill, vitamin D-deficient patients


This double blinded multicentre RCT studied 1078 critically ill patients with vitamin D levels at a critically low level, less than 20ng/mL.  Patients were randomised 12 hours after admission to a single enteral dose of 540,000 IU Vitamin D or placebo, with the primary endpoint 90-day all-cause mortality. The results showed no effect of vitamin D supplementation on mortality or other non-fatal outcomes, in contrast to a study some years ago in JAMA showing patients with a vitamin D deficiency had higher rates of ICU-mortality.

Please join Prof Putensen’s session to hear more about these and the other studies he has selected as the highlights for intensive care medicine in 2020.


Read More of our special newsletter covering our virtual congress

Visit our COVID-19 Resource Hub for other news and resources.